姓名：李念光
職稱：教授
E-mail：linianguang@163.com
主要研究方向：血液腫瘤新藥物分子發現及優化
個人簡介
李念光，教授，博士生導師，現任江蘇省藥學會藥物化學專業委員會委員，南京市藥學會藥物化學與藥物分析專業委員會副主任委員。2007年博士畢業于中國藥科大學，導師尤啟冬教授。2012年赴美國哈佛大學進行訪學和合作研究，導師 E. J. Corey教授。2011年入選江蘇省333人才培養第三層次培養對象，2012年入選“教育部新世紀優秀人才支持計劃”，2013年入選江蘇省第十批“六大人才高峰”，2013年獲教育部霍英東青年教師獎三等獎。近年來主要從事血液腫瘤新藥物分子的設計與合成研究，主持10多項國家及省部級項目，在Advanced Science、Journal of Experimental & Clinical Cancer Research、Journal of Medicinal Chemistry、Journal of Chemical Information and Modeling等雜志發表SCI論文100餘篇。
承擔的主要科研項目
1. 國家自然科學基金面上項目（82373710），新型構象穩定的大環類FLT3抑制劑的設計、合成與抑制門控卡口氨基酸F691L突變導緻的急性髓性白血病耐藥活性研究，2024/01-2027/12，主持，49萬
2. 國家自然科學基金面上項目（81973171），基于結構的新型選擇性FLT3共價抑制劑的設計、合成及其對（複發性及預後不良）急性髓性白血病的生物活性研究，2020/01-2023/12，主持，55萬
代表性論文
1. Nian-Guang Li* et al. PNPO-mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β-catenin Pathway. Advanced Science, 2025, 12(5), 2407681. (IF 14.2994)
2. Nian-Guang Li* et al. Design, Synthesis and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of non-Hodgkin’s Lymphoma. Journal of Medicinal Chemistry, 2025, 68(1), 108-134. (IF 6.7996)
3. Nian-Guang Li* et al. Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations. Journal of Medicinal Chemistry, 2024, 67(24), 21752-21780. (IF 6.7996)
4. Nian-Guang Li* et al. The Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonist for the Treatment of Rheumatoid Arthritis. Journal of Medicinal Chemistry, 2024, 67(22), 20315-20342. (IF 6.7996)
5. Nian-Guang Li* et al. Discovery of RORγ Allosteric Fluorescent Probes and the Application: Fluorescence Polarization, Screening and Bioimaging. Journal of Medicinal Chemistry, 2024, 67(5), 4194−4224. (IF 6.7996)
6. Nian-Guang Li* et al. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations. Journal of Medicinal Chemistry, 2024, 67(6), 6, 4346-4375. (IF 6.7996)
7. Nian-Guang Li* et al. Medicinal chemistry strategies for the development of Bruton’s tyrosine kinase inhibitors against resistance. Journal of Medicinal Chemistry, 2022, 65, 7415−7437. (IF 6.7996)
8. Nian-Guang Li* et al. Small-molecule Fms-like tyrosine kinase 3 inhibitors: An attractive and efficient method for the treatment of acute myeloid leukemia. Journal of Medicinal Chemistry, 2020, 63(21), 12403−12428. (IF 6.7996)
9. Nian-Guang Li* et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. Journal of Experimental & Clinical Cancer Research, 2022, 41:11. (IF 11.3997)
10. Nian-Guang Li* et al. Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery. Journal of Chemical Information and Modeling, 2024, 64(24), 9528−9550. (IF 5.5999)
